Journal Mobile Options
Table of Contents
Vol. 36, No. 5-6, 2013
Issue release date: December 2013
Dement Geriatr Cogn Disord 2013;36:319-328
(DOI:10.1159/000351677)

Association between EEG Abnormalities and CSF Biomarkers in a Memory Clinic Cohort

Kramberger M.G. · Kåreholt I. · Andersson T. · Winblad B. · Eriksdotter M. · Jelic V.
aDepartment of Neurobiology, Care Sciences and Society, bAlzheimer Research Centre, cAging Research Centre, and dDepartment of NVS, Karolinska Institutet, eStockholm University, and Departments of fClinical Neurophysiology and gGeriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, and hInstitute for Gerontology, School of Health Sciences, Jönköping University, Jönköping, Sweden; iDepartment of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The aim of the study was to describe distinct electroencephalogram (EEG) phenotypes defined after routine visual EEG analysis in a large memory clinic cohort and to investigate their relationship to cerebrospinal fluid (CSF) biomarkers. Methods: Patients with Alzheimer's disease (n = 131), mild cognitive impairment (n = 285), subjective cognitive impairment (n = 310), and mixed dementia (n = 29) were assessed clinically with neuroimaging, EEG and CSF investigations. EEG phenotypes were based on frequency of background activity (BA) and presence and degree of episodic abnormalities (EA). Results: BA and EA differed significantly (p < 0.001) between diagnostic groups. A lower CSF amyloid β42/phospho-tau ratio and higher total tau were associated with slower BA (p < 0.01) and a higher degree of EA (p < 0.04). Conclusions: Slowing of BA in combination with EA seems to be related to biological markers of neurodegeneration. © 2013 S. Karger AG, Basel



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Andersson C, Lindau M, Almkvist O, Engfeldt P, Johansson SE, Eriksdotter Jönhagen M: Identifying patients at high and low risk of cognitive decline using Rey Auditory Verbal Learning Test among middle-aged memory clinic outpatients. Dement Geriatr Cogn Disord 2006;21:251-259.
  2. Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, Barkhof F, Blankenstein MA, Scheltens P: CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007;28:1070-1074.
  3. De Leon MJ, Mosconi L, Blenow K, DeSanti S, Zinkovski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J, Rusinek H: Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann NY Acad Sci 2007;1097:114-145.
  4. Dubois B, Feldman HH, Jacova C DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Menguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-746.
  5. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P: Revising the definition of Alzheimer's disease: a new lexicon. Lancet 2010;9:118-127.
  6. Gauthier S, Patterson C, Gordon M, Soucy JP, Schubert F, Leuzy A: Commentary on ‘Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease'. A Canadian perspective. Alzheimer Dementia 2011;7:330-332.

    External Resources

  7. Nuwer M: Assessment of digital EEG, quantitative EEG, and EEG brain mapping: report of the American Academy of Neurology and the American Clinical Neurophysiological Society. Neurology 1997;49:277-292.
  8. Jelic V, Kowalski J: Evidence-based evaluation of diagnostic accuracy of resting EEG in dementia and mild cognitive impairment. Clin EEG Neurosci 2009;40:129-142.
  9. Coben LA, Danziger W, Storandt M: A longitudinal EEG study of mild senile dementia of Alzheimer type: changes at 1 year and at 2.5 years. Electroencephalogr Clin Neurophysiol 1985;61:101-112.
  10. Soininen H, Partanen J, Laulumaa V, Helkala EL, Laakso M, Riekkinen PJ: Longitudinal EEG spectral analysis in early stage of Alzheimer's disease. Electroencephalogr Clin Neurophysiol 1989;72:290-297.
  11. Hooijer C, Jonker C, Posthuma J, Visser SL: Reliability, validity and follow-up of the EEG in senile dementia: sequelae of sequential measurement. Electroencephalogr Clin Neurophysiol 1990;76:400-412.
  12. Duffy FH, McAnulty GB, Albert MS: Temporoparietal electrophysiological differences characterize patients with Alzheimer's disease: a split-half replication study. Cereb Cortex 1995;5:215-221.
  13. Jelic V, Shigeta M, Julin P, Nordberg A, Winblad B, Wahlund LO: Quantitative electroencephalography power and coherence in Alzheimer's disease and mild cognitive impairment. Dementia 1996;7:314-323.
  14. Claus JJ, Kwa VIH, Teunisse S: Slowing on quantitative spectral EEG is a marker for rate of subsequent cognitive and functional decline in early Alzheimer disease. Alzheimer Dis Assoc Disorder 1998;12:167-174.
  15. Huang C, Wahlund LO, Dierks T: Discrimination of Alzheimer's disease and mild cognitive impairment by equivalent EEG sources: a cross-sectional and longitudinal study. Clin Neurophysiol 2000;111:1961-1967.
  16. Babiloni C, Ferri R, Moretti DV: Abnormal fronto-parietal coupling of brain rhythms in mild Alzheimer's disease: a multicentric EEG study. Eur J Neurosci 2004;19:2583-2590.
  17. Koenig T, Prichep L, Dierks T, Hubl D, Wahlund LO, John ER, Jelic V: Decreased EEG synchronisation in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2005;26:165-171.
  18. Prichep LS, John ER, Ferris SH, Rausch L, Fang Z, Cancro R, Torossian C, Reisberg B: Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imaging. Neurobiol Aging 2006;27:471-481.
  19. Dierks T, Jelic V, Pascual-Marqui RD, Wahlund L, Julin P, Linden DE, Maurer K, Winblad B, Nordberg A: Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. Clin Neurophysiol 2000;11:1817-1824.

    External Resources

  20. Van der Hiele K, Vein AA, Reijntjes RHAM, Westendorp RG, Bollen EL, van Buchem MA, van Dijk JG, Middelkoop HA: EEG correlates in the spectrum of cognitive decline. Clin Neurophysiol 2007;118:1931-1939.
  21. Claus JJ, Ongerboer de Visser BW, Bour LJ, Walstra GJ, Hijdra A, Verbeeten B Jr, Van Royen EA, Kwa VI, van Gool WA: Determinants of quantitative spectral electroencephalography in early Alzheimer's disease: cognitive functioning, regional cerebral blood flow, and computed tomography. Dement Geriatr Cogn Disord 2000;11:81-89.
  22. Dierks T, Frölich L, Ihl R, Maurer K: Correlation between cognitive brain function and electrical brain activity in dementia of Alzheimer type. J Neural Transm Gen Sect 1995;99:55-62.
  23. Jelic V, Blomberg M, Dierks T, Basun H, Shigeta M, Julin P, Jensen M, Lannfelt L, Winblad B, Wahlund LO: EEG slowing and cerebrospinal fluid tau levels in patients with cognitive decline. Neuroreport 1998;9:157-160.
  24. Stomrud E, Hansson O, Minthon L, Blennow K, Rosen I, Londos E: Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. Neurobiol Aging 2010;31:215-223.
  25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
  26. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-246.
  27. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K: Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-345.
  28. Jonker C, Geerlings MI, Schmand B: Are memory complaints predicitive of dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry 2000;15:983-991.
  29. Visser PJ, Kester A, Jolles J, Verhey F: Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006;67:1201-1207.
  30. Andreasen N, Blenow K: CSF-biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 2005;107:165-173.
  31. Rodriguez G, Arnaldi D, Picco A: Brain functional network in Alzheimer's disease: diagnostic markers for diagnosis and monitoring. Int J Alzheimers Dis 2011;2011:481903.
  32. Rae-Grant A, Blume W, Lau C, Hachinski VC, Fisman M, Merskey H: The electroencephalogram in Alzheimer-type dementia. A sequential study correlating the electroencephalogram with psychometric and quantitative pathologic data. Arch Neurol 1987;44:50-54.
  33. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC: Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer's disease. Arch Neurol 2001;58:1395-1402.
  34. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH: Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:257-262.
  35. Liedorp M, van der Flier WM, Hoogervorst ELJ, Scheltens P, Stam CJ: Associations between patterns of EEG abnormalities and diagnosis in a large memory clinic cohort. Dement Geriatr Cogn Disord 2009;27:18-23.
  36. Robinson DJ, Merskey H, Blume WT, Fry R, Williamson PC, Hachinski VC: Electroencephalography as an aid in the exclusion of Alzheimer's disease. Arch Neurol 1994;51:280-284.
  37. Snyder MS, Hall JR, Cornwell SL, Falk JD: Addition of EEG improves accuracy of a logistic model that uses neuropsychological and cardiovascular factors to identify dementia and MCI. Psychiatry Res 2011;186:97-102.
  38. Meyer JS, Rauch GM, Rauch RA, Haque A, Crawford K: Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. Ann NY Acad Sci 2000;903:411-423.
  39. De la Torre JC: Is Alzheimer's disease neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004;3:184-190.
  40. Smits LL, Liedorp M, Koene T, Roos-Reuling IE, Lemstra AW, Scheltens P, Stam CJ, van der Flier WM: EEG abnormalities are associated with different cognitive profiles in Alzheimer's disease. Dement Geriatr Cogn Disord 2011;31:1-6.
  41. De Waal H, Stam CJ, Blankenstein MA, Pijnenburg YA, Scheltens P, van der Flier WM: EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity. J Neurol Neurosurg Psychiatry 2011;82:67-71.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50